Copaxone®

DRUG2 trials

Sponsors

EMD Serono, Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 4

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

CompletedNCT00078338

EMD SeronoRelapsing-remitting Multiple Sclerosis

Start: 2004-02-16End: 2006-11-28Updated: 2018-06-27

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

CompletedNCT02499900

Teva Branded Pharmaceutical Products R&D, Inc.Multiple Sclerosis

Start: 2015-08-10End: 2017-06-02Updated: 2021-12-09

Related Papers

Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.

2019-05-0911 citations

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.

2008-09-11327 citations